Network meta-analysis of second line and beyond treatment options in metastatic clear cell renal cell carcinoma

CONCLUSION: Based on OS and PFS, the lenvtatinib + everolimus combination yielded superior, followed by cabozantinib and Lenvatinib monotherapies; all were limited by a worse SAE profile. Nivolumab and pazopanib had the lowest odds of SAEs.PMID:38216444 | DOI:10.1016/j.urolonc.2023.12.002

Source: Urologic Oncology - January 12, 2024 Category: Urology & Nephrology Authors: Mavis Obeng-Kusi Jordyn J Kreutzfeldt Ricardo J Estrada-Mendizabal Briana M Choi Ivo Abraham Alejandro Recio-Boiles Source Type: research